Seroatlas · Human Serome Atlas

FGFBP3

Fibroblast growth factor-binding protein 3

Also known as: C10orf13, FGFP3_HUMAN, MGC39320

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8TAT2
Gene: FGFBP3
Ensembl: ENSG00000174721
Chromosome: 10
Canonical length: 258 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted in brain

OverviewNCBI Gene

Enables fibroblast growth factor binding activity and heparin binding activity. Acts upstream of or within positive regulation of fibroblast growth factor receptor signaling pathway and positive regulation of vascular permeability. Located in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

258 residues, UniProt reviewed canonical sequence.

>Q8TAT2|FGFBP3
     1  MTPPKLRASL SPSLLLLLSG CLLAAARREK GAASNVAEPV PGPTGGSSGR FLSPEQHACS
    61  WQLLLPAPEA AAGSELALRC QSPDGARHQC AYRGHPERCA AYAARRAHFW KQVLGGLRKK
   121  RRPCHDPAPL QARLCAGKKG HGAELRLVPR ASPPARPTVA GFAGESKPRA RNRGRTRERA
   181  SGPAAGTPPP QSAPPKENPS ERKTNEGKRK AALVPNEERP MGTGPDPDGL DGNAELTETY
   241  CAEKWHSLCN FFVNFWNG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FGFBP3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.52
Highest tissue expression: 10 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 10 nTPM
amygdala: 5.8 nTPM
hypothalamus: 5.7 nTPM
hippocampal formation: 4.8 nTPM
basal ganglia: 4.2 nTPM
retina: 4.2 nTPM

Single-cell type

müller glia: 22 nCPM
neuroendocrine cells: 16 nCPM
epididymal principal cells: 16 nCPM
pancreatic islet cells: 11 nCPM
epididymal efferent duct absorptive cells: 8 nCPM
oligodendrocyte progenitor cells: 7.8 nCPM

Immune cell

naive B-cell: 1.7 nTPM
memory B-cell: 0.8 nTPM
basophil: 0.6 nTPM
gdT-cell: 0.5 nTPM
naive CD4 T-cell: 0.5 nTPM
naive CD8 T-cell: 0.4 nTPM

Brain region

hypothalamus: 6.4 nTPM
medulla oblongata: 6 nTPM
white matter: 5.9 nTPM
amygdala: 5.6 nTPM
midbrain: 5.3 nTPM
cerebral cortex: 5.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.89
gnomAD pLI: 0
gnomAD missense Z: -0.66
DepMap mean gene effect: -0.03
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FGFBP3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

FGF2

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FGFBP3 as an antibody target. Whether an autoantibody or antibody against FGFBP3 could matter depends on whether native FGFBP3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FGFBP3 is annotated as secreted, so native FGFBP3 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label FGFBP3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...